CL2020000892A1 - Métodos para tratar infecciones bacterianas. - Google Patents

Métodos para tratar infecciones bacterianas.

Info

Publication number
CL2020000892A1
CL2020000892A1 CL2020000892A CL2020000892A CL2020000892A1 CL 2020000892 A1 CL2020000892 A1 CL 2020000892A1 CL 2020000892 A CL2020000892 A CL 2020000892A CL 2020000892 A CL2020000892 A CL 2020000892A CL 2020000892 A1 CL2020000892 A1 CL 2020000892A1
Authority
CL
Chile
Prior art keywords
subject
methods
subjects
transplantation
bacterial infections
Prior art date
Application number
CL2020000892A
Other languages
English (en)
Inventor
Michael N Dudley
Elizabeth Alexander
Jeff Loutit
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65994826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020000892(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of CL2020000892A1 publication Critical patent/CL2020000892A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODOS PARA TRATAR UNA INFECCIÓN BACTERIANA EN SUJETOS INMUNOCOMPROMETIDOS Y SUJETOS CON UNA O MÁS NEOPLASIAS SUBYACENTES INCLUYEN ADMINISTRAR UNA COMBINACIÓN DE MEROPENEM Y VABORBACTAM AL SUJETO. LOS SUJETOS ADECUADOS A SER TRATADOS PUEDEN INCLUIR UN SUJETO CON UN HISTORIAL DE LEUCEMIA O LINFOMA EN CURSO, UN SUJETO QUE HA TENIDO TRASPLANTE DE ÓRGANOS, TRASPLANTE DE CÉLULAS MADRE, TRASPLANTE DE MÉDULA ÓSEA, O ESPLENECTOMÍA, UN SUJETO QUE RECIBE MEDICAMENTOS INMUNOSUPRESORES, UN SUJETO QUE RECIBE QUIMIOTERAPIA ABLATIVA DE MÉDULA ÓSEA, UN SUJETO CON NEUTROPENIA Y UN SUJETO QUE TIENE O HA TENIDO UNA NEOPLASIA.
CL2020000892A 2017-10-03 2020-04-02 Métodos para tratar infecciones bacterianas. CL2020000892A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762567702P 2017-10-03 2017-10-03
US201862657402P 2018-04-13 2018-04-13

Publications (1)

Publication Number Publication Date
CL2020000892A1 true CL2020000892A1 (es) 2020-10-23

Family

ID=65994826

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000892A CL2020000892A1 (es) 2017-10-03 2020-04-02 Métodos para tratar infecciones bacterianas.

Country Status (16)

Country Link
US (3) US11376237B2 (es)
EP (1) EP3691652A4 (es)
JP (1) JP2020536092A (es)
KR (1) KR20200066664A (es)
CN (1) CN111432821A (es)
AU (1) AU2018345317B2 (es)
BR (1) BR112020006658A2 (es)
CA (1) CA3078238A1 (es)
CL (1) CL2020000892A1 (es)
JO (1) JOP20200075A1 (es)
MX (1) MX2020003670A (es)
MY (1) MY200934A (es)
PH (1) PH12020550249A1 (es)
SG (1) SG11202003009QA (es)
TW (2) TW202400146A (es)
WO (1) WO2019070591A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020006658A2 (pt) 2017-10-03 2020-09-24 Melinta Therapeutics, Inc. métodos de tratamento de infecções bacterianas
EP4313033A4 (en) * 2021-03-24 2025-04-23 Trustees Of Tufts College BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912363A (zh) 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
PL3412676T3 (pl) 2010-08-10 2021-04-06 Melinta Therapeutics, Inc. Cykliczne pochodne estrowe kwasu boronowego, sposób otrzymywania oraz ich zastosowania terapeutyczne
CN102188395B (zh) 2011-04-29 2012-12-05 石药集团中诺药业（石家庄）有限公司 一种更稳定的美罗培南注射剂及其制备方法
CN102335137B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种含美罗培南的药物组合物
CN102335136B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种供注射用美罗培南药物组合物及其制备方法
CN102525961B (zh) 2012-01-17 2013-02-13 山东罗欣药业股份有限公司 美罗培南组合物注射用粉针剂
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN103570718B (zh) 2012-07-31 2016-06-29 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
CN105246476B (zh) 2013-05-28 2019-11-15 莫弗凯姆联合化学股份公司 含噁唑烷酮-喹诺酮的联合疗法在治疗细菌感染中的应用
AU2016252555A1 (en) * 2015-04-24 2017-11-09 Melinta Therapeutics, Inc. Methods of treating bacterial infections
EP4112057A1 (en) 2015-07-09 2023-01-04 Washington University Compositions and methods of use of antibacterial drug combinations
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
NZ755141A (en) 2017-01-09 2023-01-27 Melinta Therapeutics Inc Methods of treating bacterial infections
BR112020006658A2 (pt) 2017-10-03 2020-09-24 Melinta Therapeutics, Inc. métodos de tratamento de infecções bacterianas

Also Published As

Publication number Publication date
JOP20200075A1 (ar) 2020-04-30
MX2020003670A (es) 2020-08-03
PH12020550249A1 (en) 2021-02-15
EP3691652A1 (en) 2020-08-12
US20220288024A1 (en) 2022-09-15
AU2018345317B2 (en) 2024-10-24
CN111432821A (zh) 2020-07-17
AU2018345317A1 (en) 2020-05-07
KR20200066664A (ko) 2020-06-10
TW201922241A (zh) 2019-06-16
JP2020536092A (ja) 2020-12-10
US20260102374A1 (en) 2026-04-16
BR112020006658A2 (pt) 2020-09-24
US11376237B2 (en) 2022-07-05
SG11202003009QA (en) 2020-04-29
US12533342B2 (en) 2026-01-27
MY200934A (en) 2024-01-24
CA3078238A1 (en) 2019-04-11
EP3691652A4 (en) 2021-07-07
US20200297695A1 (en) 2020-09-24
WO2019070591A1 (en) 2019-04-11
TW202400146A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2022006427A (es) "construcciones para terapia génica con microdistrofina y uso de las mismas.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX2018015184A (es) Métodos para el diagnóstico de infecciones bacterianas y virales.
EA202191557A1 (ru) Комбинированная терапия радиоиммуноконъюгатами и ингибиторами репарации повреждений днк
MX2015008241A (es) Metodos para el tratamiento de espasmos gastrointestinales.
ECSP21026021A (es) Moduladores de la expresión de pnpla3
CL2020002915A1 (es) Composiciones para el tratamiento de condiciones de la piel
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
MX2017002382A (es) Metodos para tratar el mieloma multiple con compuestos imunomodulares en combinacion con anticuerpos.
MX363678B (es) Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.
MX2021000719A (es) Composicion de microbiota fecal, para su uso en la reduccion de la inflamacion inducida por tratamiento.
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
MX393900B (es) Uso de gaboxadol en el tratamiento de tinnitus.
MX2018006531A (es) Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada.
PH12021550122A1 (en) Solubilized apyrases, methods and use
ES2525137R2 (es) Agentes para tratar el mieloma múltiple
MX2025011391A (es) Batas quirurgicas
MX2017015293A (es) Composicion para tratar lesiones tisulares.
CL2021001246A1 (es) Moduladores de expresión irf5.
CL2020003169A1 (es) Métodos de uso de cd24 para prevenir y tratar la recaída de la leucemia